Mettler-Toledo International (MTD) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
8 May, 2026Executive summary
Q1 2026 reported sales grew 7% year-over-year to $947.1 million, with local currency sales up 3% (1% excluding acquisitions).
Adjusted EPS increased 9% to $8.91, supported by margin initiatives and innovation investments, while reported EPS was $8.33, up from $7.81.
Growth was driven by strong industrial and food retailing segments, with continued investments in automation, digital tools, and field organization.
Management remains confident in achieving solid adjusted EPS growth for the full year, maintaining agility and execution focus despite macroeconomic uncertainty.
The company offset 2025 tariff impacts and is monitoring new global trade and geopolitical risks.
Financial highlights
Net sales reached $947.1 million, up from $883.7 million in Q1 2025, with 3% local currency growth and 7% reported growth.
Adjusted operating profit was $246.2 million, up 4% year-over-year; adjusted operating margin at 26.0%, down 80 bps.
Gross profit margin was 58.7%, down from 59.5% a year ago, mainly due to tariffs and currency effects.
Adjusted free cash flow was $119.7 million, impacted by higher tax payments.
Diluted EPS was $8.33, up from $7.81 last year; net earnings for the quarter were $169.5 million, up 4%.
Outlook and guidance
Full-year 2026 local currency sales growth forecast at ~4%, with acquisitions contributing less than 1%.
Adjusted EPS guidance raised to $46.30–$46.95, representing 8–10% growth.
Q2 2026 local currency sales expected to grow ~3%; adjusted EPS guidance of $10.70–$10.85 (6–8% growth).
Free cash flow expected at ~$900 million for 2026; share repurchases of $825–$875 million planned.
Management expects sufficient liquidity for foreseeable needs, with ongoing monitoring of global trade, tariffs, and geopolitical risks.
Latest events from Mettler-Toledo International
- Annual meeting covers director elections, auditor ratification, and performance-based executive pay.MTD
Proxy Filing18 Mar 2026 - Director elections, auditor ratification, and say-on-pay vote set for May 7, 2026.MTD
Proxy Filing18 Mar 2026 - Q4 2025 saw 8% sales and EPS growth, with a strong 2026 outlook despite market headwinds.MTD
Q4 20256 Feb 2026 - Q2 sales fell 4%, but margin gains and service growth led to raised full-year guidance.MTD
Q2 20242 Feb 2026 - Q3 adjusted EPS up 4% on 1% sales growth; Laboratory and Service led gains amid soft markets.MTD
Q3 202415 Jan 2026 - Manufacturing flexibility, innovation, and operational programs drive growth and margin expansion.MTD
Stifel 2024 Healthcare Conference13 Jan 2026 - Innovation, digitalization, and margin expansion fuel global growth and shareholder value.MTD
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Lab and service growth offset China industrial softness; cautious 2025 outlook with service focus.MTD
7th Annual Evercore ISI HealthCONx Conference11 Jan 2026 - Innovation, digitalization, and service drive growth, with margin expansion and 2025 recovery expected.MTD
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026